Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cohen, M. A.
Right arrow Articles by Gracheck, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M. A.
Right arrow Articles by Gracheck, S. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 40, 205-211, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy


ORIGINAL ARTICLES

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin

MA Cohen, MD Huband, JW Gage, SL Yoder, GE Roland and SJ Gracheck
Therapeutics Department, Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105-2495, USA.

Clinafloxacin and trovafloxacin are two new fluoroquinolones for which few comparative data are available. When MICs of ciprofloxacin against Gram-positive and Gram-negative nosocomial species were compared, clinafloxacin was the most potent although trovafloxacin was also more active than ciprofloxacin against Staphylococcus aureus and enterococci. All three drugs were bactericidal. Clinafloxacin displayed the lowest frequency of resistance, approximating 10(-11). Development of resistance studies over 13-14 passages in the presence of drug revealed a 32-fold increase in MIC of clinafloxacin against S. aureus compared with 512- and 1024-fold for trovafloxacin and ciprofloxacin respectively, although the three drugs were comparable against Enterococcus faecalis and the Gram-negative bacilli.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
E. J. Randinitis, J. I. Brodfuehrer, I. Eiseman, and A. B. Vassos
Pharmacokinetics of Clinafloxacin after Single and Multiple Doses
Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2529 - 2535.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. J. Randinitis, J. R. Koup, G. Rausch, R. Abel, N. J. Bron, N. J. Hounslow, A. B. Vassos, and A. J. Sedman
Clinafloxacin Pharmacokinetics in Subjects with Various Degrees of Renal Function
Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2536 - 2542.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. J. Randinitis, C. W. Alvey, J. R. Koup, G. Rausch, R. Abel, N. J. Bron, N. J. Hounslow, A. B. Vassos, and A. J. Sedman
Drug Interactions with Clinafloxacin
Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2543 - 2552.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
H. Oh, N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund
gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains
Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1977 - 1981.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. Siami, N. Christou, I. Eiseman, K. J. Tack, and the Clinafloxacin Severe Skin And Soft Tissue Infe
Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections
Antimicrob. Agents Chemother., February 1, 2001; 45(2): 525 - 531.
[Abstract] [Full Text]


Home page
J Antimicrob ChemotherHome page
E. S. R. Darley, A. P. MacGowan, R. A. Howe, and C. M. Tobin
Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration
J. Antimicrob. Chemother., June 1, 2000; 45(6): 927 - 928.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. R. Snydman, N. V. Jacobus, L. A. McDermott, and S. E. Supran
Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilis Group: Effect of the Medium on Test Results
Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1710 - 1712.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
D. Milatovic, F.-J. Schmitz, S. Brisse, J. Verhoef, and A. C. Fluit
In Vitro Activities of Sitafloxacin (DU-6859a) and Six Other Fluoroquinolones against 8,796 Clinical Bacterial Isolates
Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1102 - 1107.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
C. L. Clark, M. R. Jacobs, and P. C. Appelbaum
Activities of Clinafloxacin, Alone and in Combination with Other Compounds, against 45 Gram-Positive and -Negative Organisms for Which Clinafloxacin MICs Are High
Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2295 - 2298.
[Abstract] [Full Text]


Home page
J. Clin. Microbiol.Home page
C. D. Steward, S. A. Stocker, J. M. Swenson, C. M. O'Hara, J. R. Edwards, R. P. Gaynes, J. E. McGowan Jr., and F. C. Tenover
Comparison of Agar Dilution, Disk Diffusion, MicroScan, and Vitek Antimicrobial Susceptibility Testing Methods to Broth Microdilution for Detection of Fluoroquinolone-Resistant Isolates of the Family Enterobacteriaceae
J. Clin. Microbiol., March 1, 1999; 37(3): 544 - 547.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
L. J. V. Piddock, M. Johnson, V. Ricci, and S. L. Hill
Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract
Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2956 - 2960.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum
Comparative Activities of Clinafloxacin against Gram-Positive and -Negative Bacteria
Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1269 - 1273.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.